UCB has announced that it will be amending the scope of its collaborative partnership with Otsuka Pharmaceutical, in order to focus solely on central nervous system (CNS) disorders.
Under the terms of the reorganised alliance, the companies will be discontinuing their joint work in the field of immunology, which links in with Otsuka's decision to focus its future operations on CNS disorders and oncology.
As a result of this, UCB will be continuing with the further development of its immunology pipeline in Japan independently, commencing with plans to launch its drug Cimzia in the Asian nation.
The companies stated that they remain dedicated to continuing their CNS drug development, with products such as the anti-epileptic drug E Keppra and the dopamine agonist rotigotine.
Mark McDade, executive vice-president and chief operating officer for UCB, said: "We are happy to continue our successful partnership with Otsuka Pharmaceutical in the area of CNS."
Last month, UCB announced the commencement of a new clinical study of Cimzia, which will evaluate the drug's short and long-term performance compared to a leading alternative.